Leading drug maker Ranbaxy Laboratories has received tentative approval from the US Food and Drug Administration to manufacture and market dementia drug galantamine hydrobromide. Being the first company to receive the approval, Ranbaxy is anticipating a 180-day market exclusivity for the product in the world
